SG10201911989SA - Biomarkers associated with lsd1 inhibitors and uses thereof - Google Patents
Biomarkers associated with lsd1 inhibitors and uses thereofInfo
- Publication number
- SG10201911989SA SG10201911989SA SG10201911989SA SG10201911989SA SG10201911989SA SG 10201911989S A SG10201911989S A SG 10201911989SA SG 10201911989S A SG10201911989S A SG 10201911989SA SG 10201911989S A SG10201911989S A SG 10201911989SA SG 10201911989S A SG10201911989S A SG 10201911989SA
- Authority
- SG
- Singapore
- Prior art keywords
- biomarkers associated
- lsd1 inhibitors
- lsd1
- inhibitors
- biomarkers
- Prior art date
Links
- 229940123628 Lysine (K)-specific demethylase 1A inhibitor Drugs 0.000 title 1
- 239000000090 biomarker Substances 0.000 title 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
- C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Analytical Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Hospice & Palliative Care (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15382310 | 2015-06-12 | ||
| EP15382369 | 2015-07-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201911989SA true SG10201911989SA (en) | 2020-02-27 |
Family
ID=56345081
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201911989SA SG10201911989SA (en) | 2015-06-12 | 2016-06-10 | Biomarkers associated with lsd1 inhibitors and uses thereof |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20180284095A1 (enExample) |
| EP (1) | EP3307909A1 (enExample) |
| JP (3) | JP6855466B2 (enExample) |
| KR (2) | KR20180011331A (enExample) |
| CN (2) | CN107849611A (enExample) |
| AU (2) | AU2016275702A1 (enExample) |
| BR (1) | BR112018075310A2 (enExample) |
| CA (1) | CA2987876A1 (enExample) |
| CY (1) | CY1121988T1 (enExample) |
| DK (1) | DK3307267T3 (enExample) |
| HR (1) | HRP20191121T1 (enExample) |
| HU (1) | HUE043954T2 (enExample) |
| IL (2) | IL256208A (enExample) |
| LT (1) | LT3307267T (enExample) |
| MX (2) | MX2017015922A (enExample) |
| MY (1) | MY190849A (enExample) |
| PT (1) | PT3307267T (enExample) |
| RU (1) | RU2768120C2 (enExample) |
| SG (1) | SG10201911989SA (enExample) |
| SM (1) | SMT201900353T1 (enExample) |
| TR (1) | TR201909353T4 (enExample) |
| WO (2) | WO2016198649A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104203914B (zh) | 2011-10-20 | 2017-07-11 | 奥瑞泽恩基因组学股份有限公司 | 作为lsd1抑制剂的(杂)芳基环丙胺化合物 |
| EP3090998A1 (en) | 2015-05-06 | 2016-11-09 | F. Hoffmann-La Roche AG | Solid forms |
| EP3307909A1 (en) * | 2015-06-12 | 2018-04-18 | Oryzon Genomics, S.A. | Biomarkers associated with lsd1 inhibitors and uses thereof |
| KR102511028B1 (ko) | 2016-03-15 | 2023-03-16 | 오리존 지노믹스 에스.에이. | 혈액 악성 종양의 치료를 위한 lsd1 억제제의 조합물 |
| SG11201807965YA (en) | 2016-03-15 | 2018-10-30 | Oryzon Genomics Sa | Combinations of lsd1 inhibitors for use in the treatment of solid tumors |
| US10780081B2 (en) | 2016-06-10 | 2020-09-22 | Oryzon Genomics, S.A. | Method of treating multiple sclerosis employing a LSD1-inhibitor |
| JP2019128317A (ja) * | 2018-01-26 | 2019-08-01 | 学校法人同志社 | 多発性硬化症の診断マーカー又は診断キット |
| WO2019211491A1 (en) * | 2018-05-04 | 2019-11-07 | Oryzon Genomics, S.A. | Stable pharmaceutical formulation |
| EP4024049A4 (en) * | 2019-12-19 | 2023-09-20 | Daegu Gyeongbuk Institute Of Science and Technology | BIOMARKER COMPOSITION FOR DIAGNOSING MILD COGNITIVE IMPAIRMENT USING NASAL FLUID SAMPLE AND METHOD FOR DIAGNOSING MILD COGNITIVE IMPAIRMENT USING SAME |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| JPH11507821A (ja) * | 1995-06-07 | 1999-07-13 | アセナ ニューロサイエンシーズ，インコーポレイテッド | トランスジェニック動物モデルを用いてアルツハイマー病治療薬を同定する方法 |
| EP1193261A1 (en) * | 2000-10-02 | 2002-04-03 | Warner-Lambert Company | New thiadiazoles and their use as phosphodiesterase-7 inhibitors |
| CN101410367A (zh) | 2005-08-10 | 2009-04-15 | 约翰·霍普金斯大学 | 多胺用在抗寄生虫与抗癌治疗学以及作为赖氨酸-特异性脱甲基酶抑制剂 |
| JP2010523685A (ja) | 2007-04-13 | 2010-07-15 | ザ・ジョンズ・ホプキンス・ユニバーシティー | リジン特異的デメチラーゼ阻害剤 |
| EP2361242B1 (en) | 2008-10-17 | 2018-08-01 | Oryzon Genomics, S.A. | Oxidase inhibitors and their use |
| EP2389362B1 (en) | 2009-01-21 | 2019-12-11 | Oryzon Genomics, S.A. | Phenylcyclopropylamine derivatives and their medical use |
| US8895526B2 (en) * | 2009-03-27 | 2014-11-25 | Cold Spring Harbor Laboratory | Identification of RNAI targets and use of RNAI for rational therapy of chemotherapy-resistant leukemia and other cancers |
| US8389580B2 (en) | 2009-06-02 | 2013-03-05 | Duke University | Arylcyclopropylamines and methods of use |
| EP2258865A1 (en) * | 2009-06-05 | 2010-12-08 | Universitätsklinikum Freiburg | Lysine-specific demethylase 1 (LSD1) is a biomarker for breast cancer |
| JPWO2010143582A1 (ja) | 2009-06-11 | 2012-11-22 | 公立大学法人名古屋市立大学 | フェニルシクロプロピルアミン誘導体及びｌｓｄ１阻害剤 |
| US9708255B2 (en) | 2009-08-18 | 2017-07-18 | Robert A. Casero | (bis)urea and (bis)thiourea compounds as epigenic modulators of lysine-specific demethylase 1 and methods of treating disorders |
| KR101736218B1 (ko) | 2009-09-25 | 2017-05-16 | 오리존 지노믹스 에스.에이. | 라이신 특이적 디메틸라아제-1 억제제 및 이의 용도 |
| US8946296B2 (en) | 2009-10-09 | 2015-02-03 | Oryzon Genomics S.A. | Substituted heteroaryl- and aryl-cyclopropylamine acetamides and their use |
| BR122019020471B1 (pt) | 2010-04-19 | 2021-06-22 | Oryzon Genomics S.A. | Inibidores da desmetilase específica para lisina 1, seus usos e método para sua identificação, e composições farmacêuticas |
| PL2560949T3 (pl) | 2010-04-20 | 2017-01-31 | Università Degli Studi Di Roma "La Sapienza" | Pochodne tranylocyprominy jako inhibitory demetylazy histonowej LSD1 i/lub LSD2 |
| WO2012013728A1 (en) * | 2010-07-29 | 2012-02-02 | Oryzon Genomics S.A. | Arylcyclopropylamine based demethylase inhibitors of lsd1 and their medical use |
| US9006449B2 (en) | 2010-07-29 | 2015-04-14 | Oryzon Genomics, S.A. | Cyclopropylamine derivatives useful as LSD1 inhibitors |
| WO2012034116A2 (en) | 2010-09-10 | 2012-03-15 | The Johns Hopkins University | Small molecules as epigenetic modulators of lysine-specific demethylase 1 and methods of treating disorders |
| WO2012045883A1 (en) | 2010-10-08 | 2012-04-12 | Oryzon Genomics S.A. | Cyclopropylamine inhibitors of oxidases |
| PE20141322A1 (es) | 2011-03-25 | 2014-10-05 | Glaxosmithkline Intellectual Property (N 2) Limited | Ciclopropilaminas como inhibidores de desmetilasa 1 especifica de lisina |
| AU2012293223B2 (en) | 2011-08-09 | 2017-03-02 | Takeda Pharmaceutical Company Limited | Cyclopropaneamine compound |
| BR112014003382B1 (pt) | 2011-08-15 | 2022-03-15 | University Of Utah Research Foundation | Análogos de (e)-n-(1-feniletilideno) benzo-hidrazida substituída como inibidores de histona desmetilase e composições farmacêuticas compreendendo-os |
| CN104203914B (zh) | 2011-10-20 | 2017-07-11 | 奥瑞泽恩基因组学股份有限公司 | 作为lsd1抑制剂的(杂)芳基环丙胺化合物 |
| UA116765C2 (uk) | 2011-10-20 | 2018-05-10 | Орізон Джіномікс, С.А. | (гетеро)арилциклопропіламіни як інгібітори lsd1 |
| JP6325449B2 (ja) | 2012-10-12 | 2018-05-16 | 武田薬品工業株式会社 | シクロプロパンアミン化合物およびその用途 |
| WO2014084298A1 (ja) | 2012-11-28 | 2014-06-05 | 京都府公立大学法人 | リシン構造を有するｌｓｄ1選択的阻害薬 |
| EP2740474A1 (en) | 2012-12-05 | 2014-06-11 | Instituto Europeo di Oncologia S.r.l. | Cyclopropylamine derivatives useful as inhibitors of histone demethylases kdm1a |
| CN103054869A (zh) | 2013-01-18 | 2013-04-24 | 郑州大学 | 含三唑基的氨基二硫代甲酸酯化合物在制备以lsd1为靶标药物中的应用 |
| WO2014164867A1 (en) | 2013-03-11 | 2014-10-09 | Imago Biosciences | Kdm1a inhibitors for the treatment of disease |
| EP3003301B1 (en) | 2013-05-30 | 2021-02-24 | Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Las Vegas | Novel suicidal lsd1 inhibitors targeting sox2-expressing cancer cells |
| AU2014281398B2 (en) | 2013-06-19 | 2018-10-04 | University Of Utah Research Foundation | Substituted (E)-N'-(1-phenylethylidene) benzohydrazide analogs as histone demethylase inhibitors |
| CN103319466B (zh) | 2013-07-04 | 2016-03-16 | 郑州大学 | 含香豆素母核的1,2,3-三唑-氨基二硫代甲酸酯化合物、制备方法及其应用 |
| AU2014306149B2 (en) | 2013-08-06 | 2019-09-19 | Imago Biosciences Inc. | KDM1A inhibitors for the treatment of disease |
| US9186391B2 (en) | 2013-08-29 | 2015-11-17 | Musc Foundation For Research Development | Cyclic peptide inhibitors of lysine-specific demethylase 1 |
| US9556170B2 (en) | 2013-08-30 | 2017-01-31 | University Of Utah Research Foundation | Substituted-1H-benzo[d]imidazole series compounds as lysine-specific demethylase 1 (LSD1) inhibitors |
| LT3080100T (lt) | 2013-12-11 | 2023-02-27 | Celgene Quanticel Research, Inc. | Lizinui specifinės demetilazės-1 inhibitoriai |
| US10118903B2 (en) | 2014-02-07 | 2018-11-06 | Musc Foundation For Research Development | Aminotriazole-based KDM1A inhibitors as epigenetic modulators |
| EP3105219B9 (en) | 2014-02-13 | 2018-10-03 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
| DK3105226T3 (da) | 2014-02-13 | 2019-10-14 | Incyte Corp | Cyclopropylaminer som lsd1-inhibitorer |
| US9527835B2 (en) | 2014-02-13 | 2016-12-27 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
| PT3105218T (pt) | 2014-02-13 | 2019-12-05 | Incyte Corp | Ciclopropilaminas como inibidores de lsd1 |
| AU2015226881A1 (en) | 2014-03-07 | 2016-09-29 | Intonation Research Laboratories | Inhibitors of histone lysine specific demethylase (LSD1) and histone deacetylases (HDACs) |
| CN103893163B (zh) | 2014-03-28 | 2016-02-03 | 中国药科大学 | 2-([1，1′-联苯]-4-基)2-氧代乙基4-((3-氯-4-甲基苯基)氨基)-4-氧代丁酸酯在制备lsd1抑制剂药物中的应用 |
| TN2016000418A1 (en) | 2014-04-11 | 2018-04-04 | Takeda Pharmaceuticals Co | Cyclopropanamine compound and use thereof. |
| CN103961340B (zh) | 2014-04-30 | 2019-06-25 | 南通中国科学院海洋研究所海洋科学与技术研究发展中心 | 一类lsd1抑制剂及其应用 |
| DK3137169T3 (da) | 2014-05-01 | 2022-02-14 | Celgene Quanticel Res Inc | Hæmmere af lysin-specifik demethylase-1 |
| DK3148974T3 (en) | 2014-05-30 | 2018-10-29 | St Europeo Di Oncologia S R L | CYCLOPROPYLAMINE COMPOUNDS AS HYDONDEMETHYLASE INHIBITORS |
| CN104119280B (zh) | 2014-06-27 | 2016-03-16 | 郑州大学 | 含氨基类脲与端炔结构单元的嘧啶衍生物、制备方法及应用 |
| PL3160956T3 (pl) | 2014-06-27 | 2020-11-30 | Celgene Quanticel Research, Inc. | Inhibitory demetylazy-1 specyficznej dla lizyny |
| LT3511319T (lt) | 2014-07-03 | 2023-08-25 | Celgene Quanticel Research, Inc. | Lizinui specifinės demetilazės-1 inhibitoriai |
| CA2954060A1 (en) | 2014-07-03 | 2016-01-07 | Celgene Quanticel Research, Inc. | Inhibitors of lysine specific demethylase-1 |
| TWI687419B (zh) | 2014-07-10 | 2020-03-11 | 美商英塞特公司 | 作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪 |
| TW201613925A (en) | 2014-07-10 | 2016-04-16 | Incyte Corp | Imidazopyrazines as LSD1 inhibitors |
| WO2016007722A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
| US9758523B2 (en) | 2014-07-10 | 2017-09-12 | Incyte Corporation | Triazolopyridines and triazolopyrazines as LSD1 inhibitors |
| MX381597B (es) | 2014-09-05 | 2025-03-12 | Celgene Quanticel Res Inc | Inhibidores demetilasa-1 específica de lisina. |
| EP2993175A1 (en) | 2014-09-05 | 2016-03-09 | IEO - Istituto Europeo di Oncologia Srl | Thienopyrroles as histone demethylase inhibitors |
| EP3307909A1 (en) * | 2015-06-12 | 2018-04-18 | Oryzon Genomics, S.A. | Biomarkers associated with lsd1 inhibitors and uses thereof |
-
2016
- 2016-06-10 EP EP16734564.4A patent/EP3307909A1/en not_active Withdrawn
- 2016-06-10 JP JP2018516634A patent/JP6855466B2/ja not_active Expired - Fee Related
- 2016-06-10 MX MX2017015922A patent/MX2017015922A/es unknown
- 2016-06-10 AU AU2016275702A patent/AU2016275702A1/en not_active Abandoned
- 2016-06-10 KR KR1020187001221A patent/KR20180011331A/ko not_active Withdrawn
- 2016-06-10 WO PCT/EP2016/063368 patent/WO2016198649A1/en not_active Ceased
- 2016-06-10 CA CA2987876A patent/CA2987876A1/en not_active Abandoned
- 2016-06-10 CN CN201680045398.8A patent/CN107849611A/zh active Pending
- 2016-06-10 SG SG10201911989SA patent/SG10201911989SA/en unknown
- 2016-06-10 US US15/735,377 patent/US20180284095A1/en not_active Abandoned
-
2017
- 2017-06-09 MY MYPI2017001810A patent/MY190849A/en unknown
- 2017-06-09 SM SM20190353T patent/SMT201900353T1/it unknown
- 2017-06-09 DK DK17735004.8T patent/DK3307267T3/da active
- 2017-06-09 JP JP2017565305A patent/JP6411680B1/ja not_active Expired - Fee Related
- 2017-06-09 BR BR112018075310-6A patent/BR112018075310A2/pt not_active Application Discontinuation
- 2017-06-09 RU RU2019100037A patent/RU2768120C2/ru active
- 2017-06-09 KR KR1020187001123A patent/KR102372194B1/ko not_active Expired - Fee Related
- 2017-06-09 MX MX2017015921A patent/MX2017015921A/es active IP Right Grant
- 2017-06-09 CN CN201780002630.4A patent/CN107921029B/zh not_active Expired - Fee Related
- 2017-06-09 TR TR2019/09353T patent/TR201909353T4/tr unknown
- 2017-06-09 HR HRP20191121TT patent/HRP20191121T1/hr unknown
- 2017-06-09 HU HUE17735004A patent/HUE043954T2/hu unknown
- 2017-06-09 LT LTEP17735004.8T patent/LT3307267T/lt unknown
- 2017-06-09 WO PCT/EP2017/064206 patent/WO2017212061A1/en not_active Ceased
- 2017-06-09 AU AU2017277751A patent/AU2017277751B2/en not_active Ceased
- 2017-06-09 PT PT17735004T patent/PT3307267T/pt unknown
- 2017-12-10 IL IL256208A patent/IL256208A/en unknown
- 2017-12-10 IL IL256207A patent/IL256207B/en unknown
-
2018
- 2018-09-21 JP JP2018177879A patent/JP2019023202A/ja active Pending
-
2019
- 2019-06-26 CY CY20191100663T patent/CY1121988T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201908301B (en) | Biomarkers and uses thereof | |
| IL277167B (en) | Cyclopropylamines as lsd1 inhibitors | |
| IL277299B (en) | Cyclopropylamines as lsd1 inhibitors | |
| IL260217B (en) | lsd1 driven | |
| IL277239B (en) | mdm2 inhibitors and combinations thereof | |
| GB201605126D0 (en) | Inhibitors and their uses | |
| IL256208A (en) | Biomarkers associated with lsd1 inhibitors and their uses | |
| SG10201911204WA (en) | Autotaxin inhibitors and uses thereof | |
| GB201400521D0 (en) | Biomarker and uses thereof | |
| HUE063848T2 (hu) | LSD1 gátlók és gyógyászati alkalmazásaik | |
| IL256096B (en) | Inhibitor of igfbp3/tmem219 axis and diabetes | |
| IL256020B (en) | Igfbp3 and uses thereof | |
| IL254916B (en) | Inhibitors and their uses | |
| IL261906A (en) | Biomarkers for proteopathies and their uses | |
| GB201512133D0 (en) | Biomarkers | |
| GB201708741D0 (en) | Biomarkers and uses thereof | |
| GB201719565D0 (en) | Biomarker and uses thereof | |
| HK1263032A1 (en) | Lsd1 inhibitors | |
| GB201505975D0 (en) | Inhibitors and their uses | |
| GB201505971D0 (en) | Inhibitors and their uses | |
| AU2014904616A0 (en) | Biomarkers and uses thereof | |
| GB201519704D0 (en) | Biomarkers | |
| GB201513683D0 (en) | Biomarkers | |
| GB201505884D0 (en) | Transcription factors and uses thereof | |
| GB201509908D0 (en) | Methods and kits |